Insider · CIK 0001110753
Carrie Smith Cox
Files at TXN (TEXAS INSTRUMENTS INC), RNAC (Cartesian Therapeutics, Inc.), OGN (Organon & Co.), SOLV (Solventum Corp). First filing May 15, 2025, latest May 14, 2026.
Carrie Smith Cox files SEC Form 4 as director and chair at OGN (Organon & Co.), and also at TXN (TEXAS INSTRUMENTS INC), RNAC (Cartesian Therapeutics, Inc.), SOLV (Solventum Corp). Since May 15, 2025, Carrie Smith Cox has reported 2 open-market buys worth $602k and 1 open-market sell worth $2.7M, the latest filed on May 14, 2026.
A track record needs three past buys with six months of prices behind them; Carrie Smith Cox has 0, so none is measured yet.
The newest scored trade: sold $2.7M of TXN on May 13, 2026, filed May 14, 2026, scored 45 (moderate). In the last 12 months: 1 buy worth $502k and 1 sell worth $2.7M.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
OGN: Organon & Co.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
TXN: TEXAS INSTRUMENTS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | TEXAS INSTRUMENTS INC | $2.7M 8,838 shares | -19% | +102% from low0% from high | |
| 56Moderate | OGNbuy Organon & Co. | $502k 65,400 shares | +525% | +22% from low-52% from high | |
| 66Notable | Organon & Co. | $101k 12,469 shares | - | 0% from low-60% from high |
Transactions
Every row this insider has filed, 23 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 15, 2026 | SOLV Solventum Corp | AGrant or award Restricted Stock Unitsderivative | +4,848 | $0.00 | $0 | 4,848 | May 18, 2026 |
| May 13, 2026 | TXN TEXAS INSTRUMENTS INC | MOption exercise Common Stock | +4,306 | $110.15 | $474k | 41,932 | May 14, 2026 |
| May 13, 2026 | TXN TEXAS INSTRUMENTS INC | MOption exercise Common Stock | +4,532 | $104.41 | $473k | 46,464 | May 14, 2026 |
| May 13, 2026 | TXN TEXAS INSTRUMENTS INC | SOpen-market sale Common Stock | -8,393 | $306.37 | $2.6M | 38,071 | May 14, 2026 |
| May 13, 2026 | TXN TEXAS INSTRUMENTS INC | SOpen-market sale Common Stock | -445 | $307.04 | $137k | 37,626 | May 14, 2026 |
| May 13, 2026 | TXN TEXAS INSTRUMENTS INC | MOption exercise NQ Stock Option (Right to Buy)derivative | -4,306 | $0.00 | $0 | 0 | May 14, 2026 |
| May 13, 2026 | TXN TEXAS INSTRUMENTS INC | MOption exercise NQ Stock Option (Right to Buy)derivative | -4,532 | $0.00 | $0 | 0 | May 14, 2026 |
| Apr 30, 2026 | SOLV Solventum Corp | MOption exercise Common Stock | +4,916 | $0.00 | $0 | 16,400 | May 1, 2026 |
| Apr 30, 2026 | SOLV Solventum Corp | MOption exercise Restricted Stock Unitsderivative | -4,916 | $0.00 | $0 | 0 | May 1, 2026 |
| Mar 27, 2026 | SOLV Solventum Corp | MOption exercise Common Stock | +6,336 | $0.00 | $0 | 11,484 | Mar 30, 2026 |
| Mar 27, 2026 | SOLV Solventum Corp | MOption exercise Restricted Stock Unitsderivative | -6,336 | $0.00 | $0 | 0 | Mar 30, 2026 |
| Jan 29, 2026 | TXN TEXAS INSTRUMENTS INC | AGrant or award Common Stock | +525 | $0.00 | $0 | 37,626 | Feb 2, 2026 |
| Jan 29, 2026 | TXN TEXAS INSTRUMENTS INC | AGrant or award NQ Stock Option (Right to Buy)derivative | +1,860 | $0.00 | $0 | 1,860 | Feb 2, 2026 |
| Nov 12, 2025 | OGN Organon & Co. | POpen-market purchase Common Stockindirect: IRA | +65,400 | $7.67 | $502k | 77,869 | Nov 13, 2025 |
| Jun 13, 2025 | OGN Organon & Co. | AGrant or award Phantom Stockderivative | +23,904 | $10.04 | $240k | 74,030 | Jun 16, 2025 |
| May 14, 2025 | OGN Organon & Co. | POpen-market purchase Common Stock | +12,469 | $8.07 | $101k | 12,469 | May 15, 2025 |
| May 13, 2025 | SOLV Solventum Corp | MOption exercise Common Stock | +5,148 | $0.00 | $0 | 5,148 | May 15, 2025 |
| May 13, 2025 | SOLV Solventum Corp | MOption exercise Restricted Stock Unitsderivative | -5,148 | $0.00 | $0 | 0 | May 15, 2025 |
| Apr 30, 2025 | SOLV Solventum Corp | AGrant or award Restricted Stock Unitsderivative | +4,916 | $0.00 | $0 | 4,916 | May 2, 2025 |
| Jan 27, 2025 | TXN TEXAS INSTRUMENTS INC | AGrant or award Common Stock | +614 | $0.00 | $0 | 37,101 | Jan 29, 2025 |
| Jan 27, 2025 | TXN TEXAS INSTRUMENTS INC | AGrant or award NQ Stock Option (Right to Buy)derivative | +2,551 | $0.00 | $0 | 2,551 | Jan 29, 2025 |
| Jan 2, 2025 | RNAC Cartesian Therapeutics, Inc. | AGrant or award Common Stock | +2,600 | $0.00 | $0 | 15,629 | Jan 6, 2025 |
| Jan 2, 2025 | RNAC Cartesian Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +8,000 | $0.00 | $0 | 8,000 | Jan 6, 2025 |
Questions about Carrie Smith Cox
Answered from the filings on this page, as of the latest one.
Is Carrie Smith Cox buying or selling?
In the last 12 months Carrie Smith Cox reported 1 open-market buy worth $502k and 1 open-market sell worth $2.7M on SEC Form 4; the latest was sold $2.7M of TXN on May 13, 2026. Grants, option exercises and tax withholding are not counted.
How did Carrie Smith Cox's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Carrie Smith Cox has 0.
Where does Carrie Smith Cox file Form 4?
Carrie Smith Cox has filed Form 4 at OGN (Organon & Co.) as Executive Chair; TXN (TEXAS INSTRUMENTS INC); RNAC (Cartesian Therapeutics, Inc.); SOLV (Solventum Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.